Results 201 to 210 of about 25,013,779 (354)

Responsible patient-centered care

Indian Journal of Endocrinology and Metabolism, 2017
Sanjay Kalra, Manash P Baruah, A G Unnikrishnan   +2 more
openaire   +3 more sources

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

GP workforce sustainability to maximise effective and equitable patient care: a realist review. [PDF]

Br J Gen Pract
Owen-Boukra E, Burford B, Cohen T, Duddy C, Dunn H, Fadia V, Goodman C, Henry C, Lamb EI, Ogden M, Rapley T, Rees EL, Roberts N, Royer-Gray E, Vance G, Wong G, Park S.   +16 more
europepmc   +1 more source

NKCC1: A key regulator of glioblastoma progression

Molecular Oncology, EarlyView.
Glioblastoma (GBM) progression is driven by disrupted chloride cotransporter homeostasis. NKCC1 is highly expressed in stem‐like, astrocytic, and progenitor cells, correlating with earlier recurrence, while overall survival remains unaffected. NKCC1 serves as a prognostic marker and potential therapeutic target, linking chloride transporter imbalance ...
Anja Thomsen, Diana Freitag, Madlen Haase, Christian Senft, Falko Schwarz, Silke Keiner   +5 more
wiley   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Risk formulation, lived experience, and patient leadership in European CAMHS

Public Health Reviews
Nadia Ahmed, Sophie Mae Harrington, Aikaterina Sidiroglou, Paul Louis Fiedler, Hannah Brunskill, Jennifer Hall, Ledia Lazeri, Joao Breda   +7 more
doaj   +1 more source

University of Alberta's Patient Care Process: A renewed fundamental framework. [PDF]

Can Pharm J (Ott)
Leslie T, Breault RR, Hall JJ.
europepmc   +1 more source

Conflating Medical Care With Patient Care [PDF]

Journal of Graduate Medical Education, 2017
openaire   +2 more sources

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

AI in hematology: A new frontier for nursing practice and patient care. [PDF]

J Family Med Prim Care
Nasiri AM, Alsalman NA, Aljandabi FA, Alsomali SA.   +3 more
europepmc   +1 more source